Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2026 · second_quarter · Q2
Rare disease drug development reciprocity across trusted nations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2026 · first_quarter · Q1
Source: Senate LDA
Rare disease drug development reciprocity across trusted nations.
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2025 · fourth_quarter · Q4
Rare disease drug development reciprocity across trusted nations.
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2025 · third_quarter · Q3
Rare disease drug development reciprocity across trusted nations.
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2025 · second_quarter · RA
Rare disease drug development reciprocity.
Rare disease drug development reciprocity.
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2025 · second_quarter · Q2
Rare disease drug development reciprocity across trusted nations.
MANAX RUTSON CLINICAL DEVELOPMENT LLC via JTB SRATEGIES
2025 · second_quarter · RR
Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.
Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.
Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.